Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques

被引:274
作者
Surrey, ES [1 ]
Schoolcraft, WB [1 ]
机构
[1] Colorado Ctr Reprod Med, Englewood, CO USA
关键词
assisted reproductive techniques; controlled ovarian hyperstimulation; poor responder; GnRH agonist;
D O I
10.1016/S0015-0282(99)00630-5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To assess the efficacy of various controlled ovarian hyperstimulation (COH) regimens in the prior poor-responder patient preparing for assisted reproductive techniques. Design: English-language literature review. Patient(s): Candidates for assisted reproductive techniques who had been defined as having a prior suboptimal response to standard COH regimens. Intervention(s): A variety of regimes are reviewed, including increased gonadotropin doses, change of gonadotropins, adjunctive growth hormone (GH), luteal phase (long) GnRH agonist (GnRH-a) initiation, early follicular phase (flare) GnRH-a initiation, low-dose luteal phase (ultrashort) GnRH-a initiation, progestin pretreatment, and microdose flare GnRH-a initiation. Main Outcome Measure(s): Maximal serum E-2 levels, follicular development, dose, and duration of gonadotropin therapy, cycle cancellation rates, oocytes retrieved, embryos: transferred, and clinical and ongoing pregnancy rates. Result(s): A lack of uniformity in definition of the poor responder and of prospective randomized trials make data interpretation somewhat difficult. Of the varied strategies proposed, those that seem to be more uniformly beneficial are microdose GnRH-a flare and late luteal phase initiation of a short course of low-dose GnRH-a discontinued before COH. Conclusion(s): No single regimen will benefit all poor responders. General acceptance of uniform definitions and performance of large-scale prospective randomized trials an critical. Development of a reliable precycle screen will allow effective differentiation among normal responders, poor responders, and those who will not conceive with their own oocytes.
引用
收藏
页码:667 / 676
页数:10
相关论文
共 89 条
[1]   INSULIN-LIKE GROWTH-FACTORS AS INTRAOVARIAN REGULATORS OF GRANULOSA-CELL GROWTH AND FUNCTION [J].
ADASHI, EY ;
RESNICK, CE ;
DERCOLE, AJ ;
SVOBODA, ME ;
VANWYK, JJ .
ENDOCRINE REVIEWS, 1985, 6 (03) :400-420
[2]   Comparison of a blocking vs. a flare-up protocol in poor responders with a normal and abnormal clomiphene citrate challenge test [J].
Anserini, P ;
Magnasco, A ;
Remorgida, V ;
Gaggero, G ;
Testa, D ;
Capitanio, GL .
GYNECOLOGICAL ENDOCRINOLOGY, 1997, 11 (05) :321-326
[3]   IN-VIVO AND IN-VITRO EFFECT OF GROWTH-HORMONE ON ESTRADIOL SECRETION BY HUMAN GRANULOSA-CELLS [J].
BARRECA, A ;
ARTINI, PG ;
DELMONTE, P ;
PONZANI, P ;
PASQUINI, P ;
CARIOLA, G ;
VOLPE, A ;
GENAZZANI, AR ;
GIORDANO, G ;
MINUTO, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (01) :61-67
[4]   Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients [J].
Battaglia, C ;
Salvatori, M ;
Maxia, N ;
Petraglia, F ;
Facchinetti, F ;
Volpe, A .
HUMAN REPRODUCTION, 1999, 14 (07) :1690-1697
[5]  
BENRAFAEL Z, 1987, FERTIL STERIL, V48, P964
[6]   THE MORPHOGENIC/CYTOTOXIC AND PROSTAGLANDIN-STIMULATING ACTIVITIES OF INTERLEUKIN-1-BETA IN THE RAT OVARY ARE NITRIC-OXIDE INDEPENDENT [J].
BENSHLOMO, I ;
ADASHI, EY ;
PAYNE, DW .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (04) :1463-1469
[7]   Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates [J].
Biljan, MM ;
Mahutte, NG ;
Dean, N ;
Hemmings, R ;
Bissonnette, F ;
Tan, SL .
FERTILITY AND STERILITY, 1998, 70 (06) :1063-1069
[8]   GROWTH-HORMONE CO-TREATMENT FOR OVULATION INDUCTION MAY ENHANCE CONCEPTION IN THE CO-TREATMENT AND SUCCEEDING CYCLES, IN CLONIDINE NEGATIVE BUT NOT CLONIDINE POSITIVE PATIENTS [J].
BLUMENFELD, Z ;
DIRNFELD, M ;
GONEN, Y ;
ABRAMOVICI, H .
HUMAN REPRODUCTION, 1994, 9 (02) :209-213
[9]  
BRZYSKI RG, 1988, FERTIL STERIL, V50, P917
[10]  
Busacca M, 1996, J REPROD MED, V41, P699